Exposure to siRNA-GalNAc Conjugates in Systems of the Standard Test Battery for Genotoxicity

Nucleic Acid Therapeutics

Volumn 26, Issue 6, 2016, Pages 363-371

  Janas, Maja M ^a   Jiang, Yongfeng ^a   Duncan, Richard G ^a   Hayes, Antoinette N ^a   Liu, Ju ^a   Kasperkovitz, Pia V ^a   Placke, Michael E ^a   Barros, Scott A ^a  

^a ALNYLAM PHARMACEUTICALS   (United States)

Author keywords

Ames; comet; genotoxicity; hPBL; micronucleus; siRNA GalNAc conjugate

Indexed keywords

CD3 ANTIGEN; N ACETYLGALACTOSAMINE; SMALL INTERFERING RNA; GLYCOCONJUGATE;

AMES TEST; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; BLOOD; BONE MARROW; CHO CELL LINE; CHROMOSOME ABERRATION; CONJUGATE; CONTROLLED STUDY; DOUBLE STRANDED DNA BREAK; EXPOSURE; FEMALE; GENOTOXICITY; GENOTOXICITY ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BIOTRANSFORMATION; CHEMISTRY; CRICETULUS; DRUG EFFECTS; ENDOCYTOSIS; HELA CELL LINE; HEP-G2 CELL LINE; METABOLISM; MICRONUCLEUS TEST; MUTAGEN TESTING; PHYSIOLOGY; PRIMARY CELL CULTURE; RAT; RNA CLEAVAGE;

ACETYLGALACTOSAMINE; ANIMALS; BIOTRANSFORMATION; BONE MARROW; CHO CELLS; CRICETULUS; DNA BREAKS, DOUBLE-STRANDED; ENDOCYTOSIS; GLYCOCONJUGATES; HELA CELLS; HEP G2 CELLS; HUMANS; LYMPHOCYTES; MICRONUCLEUS TESTS; MUTAGENICITY TESTS; PRIMARY CELL CULTURE; RATS; RNA CLEAVAGE; RNA, SMALL INTERFERING;

EID: 84994786405     PISSN: 21593337     EISSN: 21593345     Source Type: Journal    
DOI: 10.1089/nat.2016.0622     Document Type: Article

References (18)

1. Guidance on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use. (2011). ICH Harmonised Tripartite Guideline S2(R1) (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use).
2. Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. (2009). ICH Harmonised Tripartite Guideline M3(R2) (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use).
3. Ames BN, WE Durston, E Yamasaki and FD Lee. (1973). Carcinogens are mutagens: a simple test system combining liver homogenates for activation and bacteria for detection. Proc Natl Acad Sci USA 70:2281-2285.
4. Ames BN, FD Lee and WE Durston. (1973). An improved bacterial test system for the detection and classification of mutagens and carcinogens. Proc Natl Acad Sci US A 70:782-786.
5. Lee SL, P Brown, J Wang and RT Dorsam. (2013). Nonclinical safety assessments and clinical pharmacokinetics for oligonucleotides therapeutics: a regulatory perspective. In: Cheng K and Mahato RI (eds. ). Advanced Delivery and Therapeutic Applications of RNAi. John Wiley and Sons, Ltd., Chichester, ch 4, pp 63-81.
6. Berman CL, SA Barros, SM Galloway, P Kasper, FB Oleson, CC Priestley, KS Sweder, MJ Schlosser and Z Sobol. (2016). OSWG recommendations for genotoxicity testing of novel oligonucleotide-based therapeutics. Nucleic Acid Ther 26:73-85.
7. Kunz BA, SE Kohalmi, TA Kunkel, CK Mathews, EM McIntosh and JA Reidy. (1994). International Commission for Protection against Environmental Mutagens and Carcinogens. Deoxyribonucleoside triphosphate levels: a critical factor in the maintenance of genetic stability. Mutat Res 318:1-64.
8. Wang G, MM Seidman and PM Glazer. (1996). Mutagenesis in mammalian cells induced by triple helix formation and transcription-coupled repair. Science 271:802-805.
9. Saleh A. (2015). The genotoxic potential of antisense oligonucleotides. DIA/FDA Oligonucleotide-Based Therapeutic Conference, Poster No. 8.
10. Henry SP, DK Monteith, JE Matson, BH Mathison, KS Loveday, RA Winegar, PS Lee, ES Riccio, JP Bakke and AA Levin. (2002). Assessment of the genotoxic potential of ISIS 2302: a phosphorothioate oligodeoxynucleotide. Mutagenesis 17:201-209.
11. Younis HS, T Machemer, DA Norris, S Burel and SP Henry. (2013). Evaluation of antisense oligonucleotides in human PBMCs and association of release of IL-6 in vitro to constitutional symptoms. Toxicologist 132:Abstract No. 1816.
12. Yanagihara K, M Tashiro, Y Fukuda, H Ohno, Y Higashiyama, Y Miyazaki, Y Hirakata, K Tomono, Y Mizuta, K Tsukamoto and S Kohno. (2006). Effects of short interfering RNA against methicillin-resistant Staphylococcus aureus coagulase in vitro and in vivo. J Antimicrob Chemother 57: 122-126.
13. Nair JK, JL Willoughby, A Chan, K Charisse, MR Alam, Q Wang, M Hoekstra, P Kandasamy, AV Kel'in, et al. (2014). Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc 136:16958-16961.
14. Shen W, XH Liang, H Sun and ST Crooke. (2015). 2'-Fluoromodified phosphorothioate oligonucleotide can cause rapid degradation of P54nrb and PSF. Nucleic Acids Res 43:4569-4578.
15. Suh Y and MJ Benedik. (1997). Secretion of nuclease across the outer membrane of Serratia marcescens and its energy requirements. J Bacteriol 179:677-683.
16. Johnston C, B Martin, G Fichant, P Polard and JP Claverys. (2014). Bacterial transformation: distribution, shared mechanisms and divergent control. Nat Rev Microbiol 12:181-196.
17. Sinha S, AD Cameron and RJ Redfield. (2009). Sxy induces a CRP-S regulon in Escherichia coli. J Bacteriol 191:5180-5195.
18. Collins RF and JP Derrick. (2007). Wza: a new structural paradigm for outer membrane secretory proteins? Trends Microbiol 15:96-100.